KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Capital Expenditures (2016 - 2025)

Nektar Therapeutics has reported Capital Expenditures over the past 16 years, most recently at $18000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $18000.0 for Q4 2025, down 96.08% from a year ago — trailing twelve months through Dec 2025 was $171000.0 (down 88.35% YoY), and the annual figure for FY2025 was $171000.0, down 88.35%.
  • Capital Expenditures for Q4 2025 was $18000.0 at Nektar Therapeutics, down from $114000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for NKTR hit a ceiling of $5.9 million in Q4 2021 and a floor of $2000.0 in Q1 2025.
  • Median Capital Expenditures over the past 5 years was $335000.0 (2023), compared with a mean of $1.2 million.
  • Biggest five-year swings in Capital Expenditures: soared 1918.18% in 2024 and later tumbled 98.73% in 2025.
  • Nektar Therapeutics' Capital Expenditures stood at $5.9 million in 2021, then crashed by 91.32% to $512000.0 in 2022, then tumbled by 53.71% to $237000.0 in 2023, then skyrocketed by 93.67% to $459000.0 in 2024, then crashed by 96.08% to $18000.0 in 2025.
  • The last three reported values for Capital Expenditures were $18000.0 (Q4 2025), $114000.0 (Q3 2025), and $37000.0 (Q2 2025) per Business Quant data.